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Purpose: To identify new plasma proteomic markers before radio-
therapy start to predict later grade 2 radiation-induced lung tox-
icity (RILT2).
Methods: Fifty-seven patients with non-small cell lung cancer
received radiotherapy (RT) were eligible. Forty-eight patients with
minimum follow-up of 1 year, nine with RILT2 with tumor stage
matched to 39 without RILT2, were enrolled for this analysis.
Platelet-poor plasma was obtained within 2 weeks before radiother-
apy. The plasma proteomes were compared using a multiplexed
quantitative proteomics approach involving ExacTag labeling, re-
verse-phase high-performance liquid chromatography, and nano
liquid chromatography electrospray ionization tandem mass spec-
trometry. Z scores and Bonferroni-adjusted p values for the two-
sample mean comparison were used to identify the differential
protein expression between patients with and without RILT2.
Results: More than 200 proteins were identified and quantified.
After excluding proteins that were not detected in at least 40% of the
48 patient samples, C4b-binding protein alpha chain and vitronectin
had significantly higher (p  0.001 and p  0.02) expression levels
in patients with RILT2 compared with patients without RILT2.
These two proteins were validated by Western blot. Ingenuity
pathway analysis revealed that they both play important roles in the
inflammatory response and are associated with the known pathways
of radiation-induced lung damage.
Conclusions: This proteomic approach demonstrates new plasma
protein biomarkers before treatment for future studies on RILT2
prediction.
Key Words: Non-small cell lung cancer, Proteomics, Biomarker,
Radiation-induced lung toxicity.
(J Thorac Oncol. 2011;6: 1073–1078)
Approximately 60 to 70% of patients with lung cancerreceive radiation therapy (RT) at least once during the
course of their disease.1 Clinical trials showed that patients
with non-small cell lung cancer (NSCLC) who received
higher radiation doses may have better local control and
survival.2–4 Nevertheless, the majority of patients do not
receive an adequate radiation dose for tumor control because
of concerns about risk estimates for the overall population to
limit the incidence of radiation-induced lung toxicity (RILT)
to within 5% in 5 years (tolerable dose [TD]5/5). Early
prediction of RILT would help physicians to stratify patients
according to their risk level for toxicity and determine an
individualized treatment regimen rather than to use the aver-
age radiation tolerance of the whole population.
Unfortunately, there are no good predictive markers
available to provide an individualized approach. A few small
series of studies have shown that transforming growth factor
beta 1 (TGF-1) is elevated at the end or during the course of
radiation, which might be correlated with radiation pneumo-
nitis and, therefore, be used as a predictive marker.5–7 Nev-
ertheless, the process of radiation damage is a complicated
pathophysiological phenomena involving many cells and cy-
tokines.7 We hypothesized that a test monitoring more pro-
teins together in the blood would estimate the specific extent
of the damage more accurately.
Pioneering work has already been performed using
proteomics tools in the search for tumor markers, demonstrat-
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ing the promise of such an effort.8,9 These studies were
mostly focused on early detection, diagnosis, staging, treat-
ment monitoring, and prognosis of lung cancer.8–12 A few
studies have reported proteomics analysis of radiation-in-
duced changes in lung cells or tissue.13–15 We have previously
demonstrated in animal studies that radiation-induced
changes in multiple proteins differ between lung fibrosis
sensitive and resistant mouse strains by proteomic ap-
proaches.16 Using ExacTag labeling, reverse-phase high-per-
formance liquid chromatography (RP-HPLC), and nano liq-
uid chromatography electrospray ionization tandem mass
spectrometry (LC-ESI-MS/MS), we recently assessed differ-
ential plasma proteomics in patients with and without grade
2 RILT (grade2 radiation-induced lung toxicity [RILT2])
in 20 patients throughout the treatment course.17 We demon-
strated that C4b-binding protein alpha chain (C4BPA), com-
plement C3, and vitronectin (VTN) had significantly higher
expression levels in patients with RILT2 compared with
patients without RILT2, based on both the longitudinal data
sets of RT start to 3 months post-RT (p  0.01) and RT start
to the end of RT (p  0.01). The purpose of this study, using
a larger number of patients, was to examine whether there is
any potential proteomic biomarkers at baseline (before radio-
therapy start) to predict the risk of RILT2.
PATIENTS AND METHODS
Study Population
This work was part of prospective clinical trials, which
were approved by the Institutional Review Board and per-
formed at the University of Michigan and the Veterans
Affairs Medical Center, Ann Arbor, MI. Written informed
consent was obtained from each patient. Eligible subjects
included patients with stages I to III NSCLC undergoing
radiation alone or combined radiation and chemotherapy.
Exclusion criteria included a life expectancy of less than 6
months, malignant pleural or pericardial effusion, or noncon-
tiguous involvement of the parietal pleura. All the irradiation
was given using the three-dimensional conformal technique,
as described previously.18,19
Plasma Sample Preparation
Platelet-poor plasma was used for proteomic analyses.
Blood samples were collected within 2 weeks before RT start
with Vacutainer plus collection tubes containing K2 ethylene-
diamine tetraacetic acid as the anticoagulant then placed in
ice immediately after collection and centrifuged within 3
hours of collection at 3000 g for 30 minutes at 4°C. The upper
one third of the supernatant was collected as platelet-poor
plasma and stored at 80°C. Pooled normal human plasma
was purchased from Innovative Research Inc. (Plymouth,
MN, Cat #: IPLA-5) as a reference control.
Proteomic Analysis
Multiplex quantitative proteomics approaches, involv-
ing ExacTag labeling, RP-HPLC, and LC-ESI-MS/MS, were
used in analyzing radiation-induced changes in plasma pro-
teins between patients with and without RILT2. The detailed
methods have been recently prescribed in our previous
work.17 In brief, the proteomic analysis includes depletion of
the 12 most abundant proteins, stable isotope sample labeling,
protein separation by RP-HPLC, peptide separation by
LC-ESI-MS/MS, protein identification by the SEQUEST al-
gorithm and Trans-Proteomic Pipeline software, and protein
quantification by ExacTag analysis software 3.0.17
Western Blotting for Validation
Western blotting was used to further validate the measure-
ment of proteomic approaches using anti-VTN antibody
(ab11591), anti-afamin (AFM) antibody (ab49139; Abcam Inc.,
Cambridge, MA), and anti-C4BPA antibody (SAB2100305;
Sigma-Aldrich, St Louis, MO). As a proof of the principle, we
randomly selected eight samples, four with higher expression
of VTN and four with lower expression of VTN. AFM was
selected to be an internal reference because the expressions of
AFM were almost the same in all samples, which were
identified from our proteomic approaches.
Statistical Considerations
The primary end point in this study was grade2 RILT
(RILT2), as it is clinically significant. The details of the
diagnosis and grading systems for RILT have been described
previously.19 Z scores for the two-sample mean difference
between log-transformed protein expression in RILT 2 and
RILT less than 2 patients were used to identify univariate
protein markers. The 80 proteins that were detected in at least
40% of the 48 patient samples were analyzed, based on the
sample size and the number of events with weighted consid-
eration on the number of proteins and cost of multiple testing.
Bonferroni-adjusted p values for these 80 Z scores were used
to identify statistically significant associations with RTIL2.
Predictive analysis was performed using ridged logistic re-
gression to adjust for potential errors from multitesting.
Cross-validation was used to produce unbiased sensitivity
and specificity estimates, which were displayed as a receiver
operating characteristic curve. The logistic regression was
based on selection of k proteins based on univariate Z scores,
which were calculated internally to the cross-validation. Pre-
dictive models using log-scale protein expression and/or
mean lung dose (MLD) were considered.
RESULTS
Patient Characteristics
Of the 57 patients enrolled, 48 patients with longer than
2-year follow-up were included into this analysis. There were
nine more than grade 2, 19 grade 1, and 20 grade 0 RILT. Our
analysis focused on the difference between patients with
RILT 2 (RILT2) and grouped RILT0 to 1 patients (without
RILT2). The patients’ characteristics are listed in Table 1.
Lung dosimetric factors such as MLD, V20, and normal
tissue complication probability (NTCP) were not significantly
different between patients with and without RILT2, largely
due to the fact that RT dose prescription was individualized
to certain fixed limits of MLD, V20, or NTCP in most
patients. Of another note, MLD, V20, and NTCP were sig-
nificantly correlated with each other (p  0.001), we elected
MLD as the representative dosimetric parameter of the lung.
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Reproducibility of the Proteomics System
The reproducibility of the proteomics system, including
isotope-labeling reagent, RP-HPLC, and nano LC-MS/MS
system, has been confirmed and reported in our recent
study.17
Plasma Proteomic Analysis between Patients
with and without RILT2
More than 200 proteins were identified and quantified
in plasma samples. A representative MS/MS spectrum of a
unique peptide from the protein VTN is shown in Figure 1.
There were four proteins with significantly different
expression between patients with and without RILT2 after
Bonferroni correction for multiple testing. The expression of
immunoglobulin (Ig) kappa chain V-III region Ti and region
HAH in patients with RILT2 was significantly lower than in
patients without RILT2, whereas the expression of C4BPA
and VTN in patients with RILT2 was significantly higher
than that in patients without RILT2 as shown in Figure 2
(adjusted p  0.001 and p  0.009, respectively).
Validation by Western Blotting
As shown in Figure 3, this monoclonal anti-VTN
antibody (Abcam Inc., #ab11591) recognizes both the 75
kDa and 65 kDa bands of human purified and plasma VTN
in an immunoblotting assay.20 VTN and C4BPA were
detected at lower levels in samples 1 to 4 than in samples
FIGURE 1. MS/MS sequencing data of a unique peptide from vitronectin identified in fractions. MS/MS, tandem mass
spectrometry.





Gender (male:female) 8:1 34:5 0.42
Age (yr) 69 (53–81)a 68 (44–85)a 0.76
Radiation dose 66 (63–75.6) Gya 67.8 (45–81.4) Gya 0.78
MLD 16.5 (9.1–20.5) Gya 14.6 (3.6–23.4) Gya 0.37
V20 27 (17–34)%a 24 (5–35)%a 0.44
NTCP 9.8 (2.9–18.7)%a 8.9 (0.8–26.2)%a 0.58
Chemotherapy 77.8 % 76.9 % 0.96
a Data presented are median (range).
RILT2, grade 2 radiation-induced lung toxicity; MLD, mean lung dose; NTCP,
normal tissue complication probability; V20, volume of both lungs (without including
the gross tumor volumes) receiving 20 Gy.
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5 to 8, whereas the reference protein AFM was detected at
similar levels of expression, which are consistent with the
results from proteomic approaches. This result suggests the
reliability of the proteomic approaches used for protein quan-
tification. VTN in the samples from patients with RILT2
presents smear bands at higher molecular weight and sug-
gesting greater glycosylation.
Predictive Models for Risk of RILT2
Ridged logistic regression was used to perform predic-
tive analysis of five models: C4BPA alone, VTN alone, MLD
alone, C4BPA  VTN, and C4BPA  VTN  MLD.
Cross-validation of unbiased sensitivity and specificity esti-
mates is displayed as receiver operating characteristic curves
with values of area under the curve (AUC), which are 0.40,
0.74, 0.49, 0.70, and 0.71 separately, as shown in Figure 4.
Although all these models were not statistically significant
(p  0.05), this result showed that three models, VTN alone,
C4BPA  VTN, and C4BPA  VTN  MLD, seemed to
have better accuracy (AUC 0.7) than MLD and other
models (AUC of 0.4–0.47) in predicting the occurrence of
RILT2. Model parameters were limited by the number of
events in this study.
DISCUSSION
In this study of 48 patients, we identified four plasma
proteins that were significantly different before the start of
treatment in patients with and without RILT2 (Figure 2): Ig
kappa chain V-III region Ti and region HAH in patients with
RILT2 were significantly lower in patients with RILT2,
whereas the expression of C4BPA and VTN was higher in
patients who later developed RILT2. This is the first human
plasma proteomics study reporting potential plasma biomark-
ers for RILT2 in patients with NSCLC before RT start. These
results represent a continuation of our recent study of 20
patients, which showed significant differences in angio-
tensinogen, complement C3, C4BPA, and VTN between
patients with NSCLC with and without RILT2 during and
after completion of RT course (from baseline to 3 months
after the end of RT).17 This study, in a larger number of
FIGURE 2. Plasma protein expressions in patients with
RILT2 (RILT2) and without RILT2 (RILT1/0). All p values are
after Bonferroni correction. RILT2, grade 2 radiation-in-
duced lung toxicity.
FIGURE 3. Validation of the proteomic approaches by
Western blotting. Lanes 1 to 4 are from the samples with
lower levels of VTN and C4BPA from patients without RILT2,
and lanes 5 to 8 are from the samples with higher levels of
VTN detected by proteomic approaches. C4BPA, C4b-bind-
ing protein alpha chain; RILT2, grade 2 radiation-induced
lung toxicity; VTN, vitronectin.
FIGURE 4. ROC curves with AUC
values of five predictive models for
grade 2 radiation-induced lung
toxicity. ROC, receiver operating
characteristic; AUC, area under the
curve; C4BPA, C4b-binding protein
alpha chain; VTN, vitronectin;
MLD, mean lung dose.
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patients, has further demonstrated a statistic significant dif-
ference in C4BPA and VTN in patients with RILT2 at
baseline (before RT start), thus suggesting the possibility for
predicting RILT2 before treatment start, which has more
important clinical implications.
C4BPA21–23 and VTN24–27 are glycoproteins, which
play important roles in radiation-induced lung damage. The
detailed functions of these proteins are complex and have
been summarized previously.17 C4BPA seems to be mainly
associated with the inflammatory complement pathway,
whereas VTN is involved in the fibrotic pathway. The high
baseline level of these two proteins may suggest higher
sensitivity of an individual to inflammatory or fibrotic patho-
genesis, thus putting this patient at a higher risk for RILT.
Changes in abundance and alternations in glycan com-
position of plasma proteins and cell-surface proteins have
been shown to correlate with cancer and other disease states.
In fact, numerous clinical biomarkers and therapeutic targets
are glycosylated proteins, such as CA125 for ovarian cancer
and the prostate-specific antigen for prostate cancer. VTN is
a glycoprotein with three N-glycosylation sites identified.28,29
Sano et al.20 reported that the changes in N-glycosylation of
VTN modulate collagen binding during liver regeneration
after partial hepatectomy. As shown in Figure 3, patients with
RILT2 might have much higher levels of glycosylated VTN
than patients without RILT2. Our future work will focus on
glycoproteome analysis of human plasma to find more de-
tailed information on the glycoproteins, which may be poten-
tial biomarkers for RILT2.
To reveal the association between our identified pro-
teins and the known pathways for radiation-induced lung
damage, we used ingenuity pathway analysis, a knowledge-
based system derived from the literature containing informa-
tion on interactions between genes, proteins, and other bio-
logical molecules, to reveal the associated biological
pathways and generate global canonical pathways that are
shown to be significantly associated with these candidates
based on their interactions.30,31 Interestingly, these proteins
were in the network of TGF-1 and interlukin-8 (Figure 5),
which are known to play important roles in the molecular
mechanism of radiation-induced lung damage.5–7,32 The net-
work illustrated implies that C4BPA and VTN have interac-
tions with TGF-1.33,34 Human TGF-1 increases production
of hydrogen peroxide,35 and hydrogen peroxide increases
expression of human C4BPA mRNA.36 This network is
further supported by our previous findings that patients with
RILT2 also had significantly higher plasma TGF-1 during
the course of radiation therapy than those without.32,37 Mul-
ticenter studies with a larger number of patients are needed to
validate these interesting findings and to study whether com-
bining all these markers together would improve the accuracy
of RILT2 prediction.
It is interesting that increases in Ig kappa chain V-III
region Ti and region HAH are associated with reduced risk of
RILT. Ig kappa chain is one type of light chain, which is the
small polypeptide subunit of an antibody (or Ig). It takes part
in any immune system process that functions in the calibrated
response of an organism to a potential internal or invasive
threat. Nevertheless, there is little literature about chain V-III
region Ti38 or region HAH.39 These fragments may have
some potential association with RILT protection and are
worthy of our further study to identify their mechanism.
In summary, this study identified VTN and C4b-bind-
ing protein alpha chain as potential blood biomarkers for
RILT2 in patients with NSCLC before RT start. A future
independent study with a larger number of patients is needed
to validate this result and confirm whether it can improve
predictive accuracy from the models (such as MLD) in
current use.
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